637338-23-9Relevant academic research and scientific papers
The role of binding constants in the efficiency of chiral catalysts immobilized by electrostatic interactions: The case of azabis(oxazoline)-copper complexes
Fraile, Jose M.,Garcia, Jose I.,Herrerias, Clara I.,Mayoral, Jose A.,Reiser, Oliver,Socuellamos, Antonio,Werner, Heiko
, p. 2997 - 3005 (2004)
As shown by theoretical calculations, azabis(oxazoline)-copper complexes are considerably more stable than the analogous bis(oxazoline)-copper complexes. This enhanced stability allows them to be efficiently immobilized by means of electrostatic interactions to different anionic supports, such as clays and nafion-silica nanocomposites, without the loss of a ligand, as is observed for bis(oxazolines). As a result, enantioselectivities of around 90% ee are obtained in the cyclopropanation reaction between styrene and ethyl diazoacetate. Moreover, the solid catalyst is easily recoverable.
Improved Synthesis of Aza-bis(oxazoline) Ligands
Werner, Heiko,Vicha, Robert,Gissibl, Anja,Reiser, Oliver
, p. 10166 - 10168 (2003)
A straightforward synthesis of chiral aza-bis-(oxazoline) (Azabox) ligands from commercially available amino alcohols is described. The new protocol allows access to previously reported Azabox ligands in considerably improved yields but also to new derivatives, including non-C2-symmetrical ones.
OXAZOLINE PSEUDODIMERS, PHARMACEUTICAL COMPOSITIONS AND THE USE THEREOF
-
Paragraph 0466;0468, (2017/12/15)
The present disclosure is directed to oxazoline mono- and hetero-pseudodimer compounds, such as compounds of Formula (I) or pharmaceutically acceptable salts or solvates thereof: These compounds are useful for treating pain. The present disclosure also relates to pharmaceutical compositions comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of Formula (I) or (II) or a pharmaceutically acceptable salt or solvate thereof
